GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Zynex Inc (NAS:ZYXI) » Definitions » Beta

Zynex (ZYXI) Beta : 0.59 (As of Apr. 30, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Zynex Beta?

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2024-04-30), Zynex's Beta is 0.59.


Zynex Beta Historical Data

The historical data trend for Zynex's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zynex Beta Chart

Zynex Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.46 1.00 0.49 0.58 0.46

Zynex Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.58 0.81 0.17 0.56 0.46

Competitive Comparison of Zynex's Beta

For the Medical Distribution subindustry, Zynex's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zynex's Beta Distribution in the Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Zynex's Beta distribution charts can be found below:

* The bar in red indicates where Zynex's Beta falls into.



Zynex Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.


Zynex  (NAS:ZYXI) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Zynex Beta Related Terms

Thank you for viewing the detailed overview of Zynex's Beta provided by GuruFocus.com. Please click on the following links to see related term pages.


Zynex (ZYXI) Business Description

Traded in Other Exchanges
N/A
Address
9555 Maroon Circle, Englewood, CO, USA, 80112
Zynex Inc is engaged in the manufacturing and marketing of medical devices. It operates through one primary business segment, Electrotherapy and Pain Management Products. The business activities of the company are carried out through its subsidiaries. The company designs, manufacture, and markets medical devices that treat chronic and acute pain, as well as activate and exercise muscles for rehabilitative purposes with electrical stimulation. it also develops and markets medical devices for non-invasive cardiac monitoring, the products of which are under development. The company markets Zynex-manufactured products which include NexWave, NeuroMove, InWave E-Wave and others.
Executives
Daniel J Moorhead officer: Chief Financial Officer 9777 PYRAMID CT, STE 100, ENGLEWOOD CO 80112
Anna Lucsok officer: See Remarks 9555 MAROON CIRCLE, ENGLEWOOD CO 80112
Thomas Sandgaard director, 10 percent owner, officer: President, CEO and Chairman 10506 KALAHARI CT., LONE TREE CO 80124
Neil Friery officer: See Remarks C/O ZYNEX, INC. 9555 MAROON CIRCLE, ENGLEWOOD CO 80112
Joshua R. Disbrow director AMPIO PHARMACEUTICALS, INC., 5445 DTC PARKWAY, SUITE 925, GREENWOOD VILLAGE CO 80111
Barry D Michaels director 6275 NANCY RIDGE DRIVE, SUITE 110, SAN DIEGO CA 92121
Michael D Cress director 3409 ESPERANZA CROSSING SUITE 7110, AUSTIN TX 78758
Sandgaard Holdings Llc 10 percent owner 9555 MAROON CIRCLE, ENGLEWOOD CO 80112
Giuseppe Papandrea officer: Chief Operating Officer C/O ZYNEX, INC. 9555 MAROON CIRCLE, ENGLEWOOD CO 80112